A Steering Board for Health should coordinate health programmes and health missions under Horizon Europe, guide applicants and create greater visibility for European health research programmes.

The outline of such a steering board for health is presented as an amendment in the proposal for a decision of the European Parliament and of the Council on establishing the specific programme implementing Horizon Europe – the Framework Programme for Research and Innovation. The BioMed Alliance supports the introduction of the amendment 551 and calls on the members of the European Parliament involved in the Horizon Europe political negotiations to maintain the Steering Board for Health proposal in the text legislation. It is time to walk the talk and to ensure deeper and longer-term collaborative and transnational initiatives that address the current gaps in the ‘innovation cycle’ and strengthen cross-fertilisation and collaboration across all relevant disciplines.

Read the BioMed Alliance statement here

On November 29, the BioMed Alliance along with a large number of European organisations involved in health and healthcare policy will host the first ever high-level EU Health Summit to discuss the future of health at EU level. Bringing together European leaders, policy makers and health stakeholders, the summit will take a fresh look into how Europe could develop and take the lead in areas such as research and innovation, health data and digital health, healthcare organisation and financing as well as health in all policies. The aim of the Summit is to distil recommendations for the next European Commission and European Parliament to bring the necessary changes about.

If you would like to attend, please Register here and find more info euhealthsummit.eu/ 

EU Health Summit final 002

The BioMed Alliance has joined 18 EU-level health organisations who have come together to ensure that the needs of patients are prioritised during the Brexit negotiations. This event will explore what pragmatic steps can be taken by EU decision-makers to ensure patients and public health are not forgotten during the Article 50 negotiations, regardless of how the talks progress. It will consider what can be done to ensure public health and health security are prioritised during those talks.

Confirmed speakers include:

  • Prof. Gerd R. Burmester - Professor of Medicine in the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University and Humboldt University of Berlin, Germany
  • Dr Gabriel Siles-Brügge - Associate Professor in Public Policy and the Programme Director for the MA in Public Policy
  • Yvonne Stewart - Head of Brexit Implementation at GlaxoSmithKline
  • Prof. Stafford Lightman - Professor of Medicine at the University of Bristol and Director of the Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology
  • Prof. Wilfried Ellmeier - Professor of Immunobiology at the Institute of Immunology, Medical University of Vienna
  • Derick Mitchell - Chief Executive of The Irish Platform for Patient Organisations, Science and Industry
  • Adina-Ioana Vălean MEP - Chair of the Committee on the Environment, Public Health and Food Safety

brexit

Registration

The event will take place on 27 September 9.00 – 11.00 am, Room 4Q2, European Parliament. If you would like to attend, please register your details by 20 September.

Precision medicine approaches the treatment of disease via an individual’s genes, environment, and lifestyle. It will allow the accurate prediction of which treatment and prevention strategies for a particular condition will work for whom – either as an individual or a group. It is therefore patient-centred as opposed to the former ‘one size fits all’ approach, and as such it needs a totally new approach, says a White Paper from the BioMed Alliance

More info here

Read the BioMed Alliance White Paper here

The BioMed Alliance supports the European Brain Council (EBC) statement “Counting down to zero: Towards a future with underfunded health research?” which calls on the European Commission, the European Parliament and the Council to increase the budget of the Horizon Europe programme to at least €120 billion, and to dedicate a much higher proportion of the research budget to the “health” cluster.

More info here

Read the European Brain Council (EBC) statement here

Read the BioMed Alliance proposals on Horizon Europe here

ERNs facilitate cross-border discussions on rare diseases or complex cases amongst clinicians and researchers. This briefing to the UK Parliament, led by Genetic Alliance UK, is aimed at producing a statement that outlines the detrimental effects that Brexit could have on patient care if negotiations don’t provide for the NHS to continue to be part of ERNs. Professor Korbonits and other eminent speakers will highlight to Members of the Parliament that continued collaboration between UK and the EU-27 is paramount to continue advancing rare disease research and patient care.

More info here

Effect of Brexit: European Reference Network : Agenda

Christian Ehler, member of the European Parliament since 2004, will visit researchers at the Charité University of Berlin and will meet with Professor Axel Pries, Dean of Charité and President of the BioMed Alliance on Friday 22 June.  Dr. Ehler has just been appointed EPP rapporteur for Horizon Europe.

More info here

The European Commission published its proposal for funding research and innovation through the Horizon Europe program from 2021 to 2027. We are concerned that health research cluster lacks the funding to meet its goals. From H2020’s lessons, the proposed budget of €7.7 billion for health research is inadequate to ensure the European Commission’s objectives, and researchers will have to face the same issues such as oversubscription and lower success rates. It is critical that a higher percentage of the research budget is dedicated to health research in order to address the various societal challenges and the expectations of EU citizens are all met.

More info here

We advocate that 25 to 30 per cent of the Horizon Europe budget should be dedicated to biomedical and health-related research. This would ensure a coherent and competitive research landscape, capable of generating benefits for individuals and economies. The Commission’s own assessment found that Horizon 2020 lacked the funding to meet its goals. This underfunding has proved a challenge for policymakers and researchers, with low success rates for applicants making it more difficult to attract high-quality proposals.  

Read the article here

The BioMed Alliance would like to express its strong support for the ERNs and laud the European Commission for its crucial, indispensable role in establishing them. We are convinced of the great potential of these networks, not just for diagnosis and treatment but also for research. We therefore call upon the European Commission to ensure the success and continuity of the ERNs by making available solid and long-term funding.

Read more here

The BioMed Alliance welcomes the European Commission's proposed budget for the next Framework Programme for Research and Innovation (Horizon Europe). We would like to take this opportunity to express our full support for an ambitious Horizon Europe, and to thank you for your commitment to promoting research as a main priority in the Multiannual Financial Framework (MFF) budget. A strong Horizon Europe will continue the track record of Horizon 2020, and will foster scientific excellence in Europe.

The BioMed Alliance, while acknowledging the multiple societal challenges that Horizon Europe has to address, is convinced that in terms of value for money, health research should be a top funding priority considering its significance for the wellbeing of EU citizens and as a driver of economic growth

Read more here

The BioMed Alliance welcomes the European Commission’s proposed budget for the next Framework Programme for Research and Innovation (Horizon Europe) within the Multiannual Financial Framework (MFF). A budget of 100 billion euro for Horizon Europe represents an increase of almost 30 per cent, and it is essential to provide effective solutions to societal challenges and foster scientific excellence in Europe.
The BioMed Alliance calls on the European Commission, European Parliament, and the Council of the EU to secure a robust budget for health research under Horizon Europe. 25-30% of the Horizon Europe budget dedicated to biomedical and health-related research will ensure a coherent, competitive European research landscape, and it will generate societal benefits and long term positive economic impact.

More info here

Better funded and better organised research programmes are an urgent priority for the health of us all.

Read the article here

Although the benefits of EU-funded health research are easy to see, such funding does not reflect the high return on investment that it provides. It will need to be substantially increased before it can do so.

More here

The subject is too important for everyone – patients, the public, and the economy – to suffer from the effect of fragmented messages.

Read more here 

The European Calcified Tissue Society (ECTS) is a non-for profit organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. Our mission is to promote excellence in research into the field of calcified tissues within Europe and beyond, and to ensure the findings are disseminated to enable benefit to patients with metabolic bone disease.  ECTS represents more than 600 members at all stages of career and has a network of over 30 national and international societies.  More information at www.ectsoc.org.

ECTS expertise and fully support will help BioMed Alliance to provide recommendations for policy and decision makers on facilitating and mproving biomedical research in Europe.  

Read the interview with Prof. Axel Pries – President of the BioMed Alliance and Prof. Gunhild Waldemar – member of the BioMed Alliance Board of Directors. Read the article here.

BioMed Alliance Member Organisations elected him at the General Assembly on 8 November 2017  for a two-year period.

Download the PDF

BioMed Alliance Board of Director Ulrich Jaeger argues that EU funding is crucial in allowing medical researchers across member states to collaborate in the development of new treatments. In Framework Programme 9, processes must be optimised and the budget boosted - to deliver for patients and the economy.  Read the article here

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.